Diluted EPS came in at $-0.19, beat the $-0.29 consensus by $0.10.
Filings will appear here once submitted to SEC EDGAR.
Common questions about XORTX Therapeutics Inc.'s Q4 2024 earnings report.
XORTX Therapeutics Inc. (XRTX) reported Q4 2024 earnings on May 15, 2025 after market close.
XORTX Therapeutics Inc. reported diluted EPS of $-0.19 for Q4 2024.
EPS beat the consensus estimate of $-0.29 by $0.10.